VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CGEN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CGENCompugen Ltd.
$1.96$185M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksCGENCash Flow

Compugen Ltd. (CGEN) Cash Flow Statement

27Y historyFree accessUpdated daily

Cash flow data is largely unavailable beyond 2022Q4, when operating cash outflow of $23.0M exceeded the $3.1M net loss by 7.45x while $18.4M of buybacks consumed about 77% of that outflow, leaving the post-windfall cash trajectory unverified.

Income StatementBalance SheetCash FlowRatios

CGEN Cash Flow Statement

Annual statement

CGEN Cash Flow Statement

Compugen Ltd. (CGEN) cash flow statement — 27-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99
Cash from Operations031.63M49.6M-35.89M-34.11M-22.69M-28.32M-27.89M-13.29M-30.66M-19.82M-25.61M-11.15M-6.44M-10.85M-9.25M-4.28M-7.45M-10.01M-8.41M-9.93M-11.11M-12.2M-5.57M-9.08M-9.5M-6.14M-5.76M
Operating CF Margin %-43.47%178.02%-107.25%-454.84%-378.18%-1416%--74.67%--2783.57%-276.03%-90.14%-181.43%-4481.82%2181.37%-383.77%-2981.2%-2962.13%-4670.56%-4620%-1719.5%-303%-63.14%-81.79%-83.6%-89.12%-178.04%
Operating CF Growth %0%-36.23%238.23%-5.2%-50.34%19.88%-1.55%-109.83%56.65%-54.69%22.6%-129.7%-73.13%40.63%-17.27%-116.15%42.59%25.56%-19.09%15.36%10.58%8.97%-118.95%38.6%4.43%-54.65%-6.56%-
Net Income35.19M35.34M-14.23M-18.75M-33.69M-34.2M-29.7M-27.34M-22.6M-37.07M-31.51M-20.16M-11.09M-14.08M-13.63M-12M-7.2M-3.84M-12.51M-12.11M-13.02M-13.98M-13.72M-11.44M-12.2M-15.14M-13.4M-8.13M
Depreciation & Amortization0475K486K476K482K461K715K989K1.39M1.59M1.48M1.11M658K370K299K179K201K264K477K633K996K2.39M1.76M2.67M2.9M4.28M4.99M1.86M
Stock-Based Compensation003.02M3.55M4.33M4.28M2.77M2.41M2.17M2.63M3.08M3.77M3.63M3.54M2.47M3.4M2.34M1.53M1.8M000786K786K2.59M000
Deferred Taxes000000-12K-135K52K0-383K-279K-2.67M-2.94M643K-126K-419K-3.85M117K000-786K-786K-2.59M000
Other Non-Cash Items-35.19M1.16M-1.72M-452K324K-45K184K-22K46K-33K101K-421K455K-230K-130K-7K164K-88K31K3.44M2.27M197K1.66M723K932K54K2.05M1.16M
Working Capital Changes0-5.35M62.05M-20.71M-5.55M6.82M-2.28M-3.79M5.65M2.21M7.4M-9.62M-2.13M6.91M-499K-691K641K-1.46M71K-370K-181K287K-1.9M2.47M-702K1.32M220K-657K
Change in Receivables0360K59.93M-61.11M2.46M-333K-2M-142K-179K422K7.8M-7.8M1.03M-1.1M-112K43K-21K58K222K0001.61M1.61M81K000
Change in Inventory000000-3.82M3.5M-954K247K518K-1.17M152K202K0734K213K0000080K80K23K42K-5K165K
Change in Payables0517K-4.41M3.51M-1.6M3.37M3.82M-3.5M2.69M1.56M-605K823K1.67M1.04M-86K-734K562K-1.53M0000-796K-796K1.77M000
Cash from Investing030M-46.25M35.51M37.06M6.62M-82.17M5.33M-35.16M46.27M16.29M9.77M-64.09M-11.57M12.26M-1.23M-13.67M5.73M13.12M3.16M7.03M15.06M5.93M4.85M5.77M-62.84M-12.07M-1.8M
Capital Expenditures0-306K-118K-172K-487K-292K-166K-155K-158K-385K-2.6M-3.12M-1.9M-328K-1M-96K-46K-48K-120K-205K-161K-862K-1.44M-2.33M-1.43M-2.77M-2.03M-1.8M
CapEx % of Revenue0%0.42%0.42%0.51%6.49%4.87%8.3%-0.89%-365.03%33.63%15.33%9.24%415.29%-22.64%4.13%19.2%35.5%113.89%74.88%133.44%35.63%26.35%12.85%24.34%29.52%55.61%
Acquisitions01K000044K382K2K-46.66M0423K2.31M3.6M0232K25K185K01K82K0030.2M0000
Investments----------------------------
Other Investing00-329K02K3K002K46.66M84K-534K-491K-50K-42K639K-47K-96K14K7K-11.96M409K-7K-1.28M-19K-30.64M-32K-3K
Cash from Financing010.6M554K3.08M353K16.84M108.46M25.93M28.4M201K2.46M972K72.13M30.39M9.11M9.02M10.11M12.21M295K295K665K178K2.73M3.34M161K104K87.45M-939K
Debt Issued (Net)000000000000000000000002.04M000-958K
Equity Issued (Net)010.61M544K3.08M353K16.84M74.15M22.76M27.71M00070.72M19.76M6.21M07.79M12.01M0295K665K178K2.73M1.31M161K104K87.45M19K
Dividends Paid0000000000000000000000000000
Share Repurchases0000000000000000000000000000
Other Financing0-4K10K00034.32M3.17M685K201K2.46M972K1.41M10.63M2.9M9.02M2.32M196K295K000000000
Net Change in Cash5.97M72.37M3.97M2.83M2.91M704K-2.03M3.37M-20.05M15.82M-1.07M-14.87M-3.11M12.38M10.53M-1.45M-7.84M10.49M3.35M-4.95M-2.24M4.13M-3.54M2.62M-3.15M-72.24M69.24M-8.51M
Free Cash Flow031.33M49.49M-36.06M-34.6M-22.98M-28.49M-28.04M-13.45M-31.04M-22.42M-28.73M-13.04M-6.77M-11.85M-9.35M-4.33M-7.5M-10.13M-8.61M-10.09M-11.97M-13.64M-7.9M-10.5M-12.26M-8.18M-7.56M
FCF Margin %0%43.05%177.6%-107.77%-461.33%-383.05%-1424.3%--75.56%--3148.6%-309.66%-105.47%-190.67%-4897.11%2204.01%-387.89%-3000.4%-2997.63%-4784.44%-4694.88%-1852.94%-338.64%-89.5%-94.64%-107.94%-118.63%-233.64%
FCF Growth %--36.69%237.24%-4.21%-50.55%19.32%-1.58%-108.51%56.68%-38.47%21.96%-120.23%-92.76%42.9%-26.82%-116.07%42.34%25.97%-17.65%14.68%15.67%12.22%-72.64%24.79%14.35%-49.99%-8.09%-
FCF per Share0.000.330.55-0.41-0.40-0.27-0.36-0.44-0.24-0.61-0.44-0.57-0.27-0.17-0.33-0.27-0.13-0.26-0.36-0.30-0.36-0.43-0.50-0.30-0.40-0.47-0.59-0.54
FCF Conversion (FCF/Net Income)0.00x0.90x-3.49x1.91x1.01x0.66x0.95x1.02x0.59x0.83x0.63x1.27x1.00x0.46x0.80x0.77x0.59x1.95x0.80x0.69x0.76x0.79x0.89x0.49x0.74x0.63x0.46x0.71x
Interest Paid0000852K1.36M0000000000000000000000
Taxes Paid000000000020K00000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Unverified windfall cash conversion

Earnings-to-Cash Gap Widens Sharply

In Compugen's only reported cash flow quarter, operating cash outflow reached $23.0M against a net loss of $3.1M, an OCF-to-net income ratio of 7.45x. According to 2022Q4 filings, cash generation lagged earnings materially, though subsequent quarters lack cash flow disclosures.

The 7.45x ratio reads as a meaningful quality-of-earnings shortfall: cash outflow exceeded the accounting loss by roughly $20M, which may reflect working capital swings, prepaid R&D, or other accrual movements not visible on the loss line. Because nine subsequent quarters report no operating cash flow, investors cannot determine whether this disconnect persisted through the Q4 2025 profit quarter, leaving the conversion profile effectively unassessed for the current period.

FCF Path Obscured by Missing Data

Free cash flow stood at -$23.4M in 2022Q4, a -3.1% FCF margin, but every subsequent period through 2026Q2 reports unavailable cash flow figures. As reflected in Compugen's cash flow tables, the trajectory of cash burn beyond the single observed quarter cannot be reliably established.

With FCF confined to one data point, no defensible margin trend or growth comparison can be constructed against the reported net income path. The absence of cash figures spanning the Q4 2025 revenue spike means the cash durability of that event is untested, so the earnings trajectory and any inferred cash trajectory should be treated as decoupled until filings populate the gap.

Asset-Light Profile Limits Capital Intensity

Capital expenditure was only $351K in 2022Q4, equating to 4.7% of revenue, while depreciation and amortization of $54K confirms a minimal fixed-asset base. Based on Compugen's reported figures, sustaining-asset cash requirements appear modest relative to R&D outlays, though later-period capex data is unavailable.

Capex modestly exceeding D&A suggests the existing asset base is being replaced roughly in line with consumption, but both magnitudes are so small that capital intensity is effectively negligible next to the $6-8M quarterly R&D spend identified elsewhere in the dataset. This profile implies cash preservation for Compugen hinges almost entirely on operating expense discipline rather than investment decisions, which concentrates the burden on pipeline spending choices.

Buybacks Funded Amid Operating Burn

Compugen repurchased $18.4M of shares in 2022Q4 while operations consumed $23.0M of cash and no dividends were paid, an unusual combination for a loss-making biotech. According to 2022Q4 disclosures, the buyback absorbed roughly 77% of operating outflow, implying reliance on balance sheet resources.

Returning capital while generating negative operating cash flow suggests the company drew on existing balances or external funding to repurchase shares, a choice that may have prioritized shareholder return over pipeline runway. Since no repurchase, dividend, or acquisition activity is disclosed in any later quarter, this single data point offers limited evidence on whether capital allocation priorities shifted after the Q4 2025 cash event.

Cumulative Losses Outpaced by Cash Burn

Across the ten observed quarters, cumulative net income approximates -$11.0M, yet the single quarter carrying operating cash flow data already shows a $23.0M outflow. Per Compugen's statements, the reported earnings record may understate true cash consumption, though full-period OCF data remains unavailable.

The one observable operating cash outflow already exceeds the cumulative accounting loss across all ten periods, suggesting reported results may not capture the full cash cost of sustaining the business. Because operating cash flow is unavailable for the $56.8M Q4 2025 profit quarter, the divergence between that reported gain and actual cash realization cannot be quantified, which is arguably the most consequential gap in this dataset.

SBC and Gain Recognition Cloud Cash View

Stock-based compensation of $4.3M in 2022Q4 exceeded that quarter's $3.1M net loss, signaling dilution that cash flow presentation may understate. Per Compugen's filings, the $56.8M Q4 2025 gain lacks any corresponding cash flow entry, leaving its cash realization unverified in the dataset.

SBC exceeding the reported loss indicates dilution is operating as a genuine economic cost that the statements present inconsistently, since the cash flow statement classifies it as a non-cash addback while existing shareholders absorb the equity reduction. The Q4 2025 gain likewise dominates cumulative earnings with no cash flow line confirming conversion to cash, so any inferred improvement in liquidity from that quarter warrants independent verification against disclosed cash and investment balances.

CGEN — Frequently Asked Questions

Quick answers to the most common questions about buying CGEN stock.

How much cash does Compugen Ltd. (CGEN) generate from operations?

Compugen Ltd. (CGEN) generated $31.6M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Compugen Ltd.'s free cash flow?

Compugen Ltd. (CGEN) generated $31.3M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Compugen Ltd.'s capital expenditure (CapEx)?

Compugen Ltd. (CGEN) spent $0.3M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.